{"id":"gs3-007a-dry-suspension","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"5-10%","effect":"Increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GS3-007a dry suspension works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is particularly useful for treating type 2 diabetes. By inhibiting SGLT2, GS3-007a dry suspension helps to decrease glucose levels in the blood, which can help to prevent complications associated with diabetes.","oneSentence":"GS3-007a dry suspension is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:39:50.468Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07473570","phase":"PHASE1","title":"A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-01-07","conditions":"Healthy Adults","enrollment":32},{"nctId":"NCT07264595","phase":"PHASE1, PHASE2","title":"A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-12","conditions":"Pediatric Growth Hormone Deficiency","enrollment":88},{"nctId":"NCT07259564","phase":"PHASE2","title":"A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-12-19","conditions":"Adult Growth Hormone Deficiency (AGHD)","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GS3-007a"],"phase":"phase_2","status":"active","brandName":"GS3-007a dry suspension","genericName":"GS3-007a dry suspension","companyName":"Changchun GeneScience Pharmaceutical Co., Ltd.","companyId":"changchun-genescience-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GS3-007a dry suspension is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}